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To the Editor:
We read the recent consensus statement from the
Worldwide Network for Blood and Marrow Trans-
plantation Standing Committee on Donor Issues
regarding the suitability criteria for adult related donors
outlined by Drs. Worel, Halter, and colleagues, published
online on August 10, 2015. We suggest that in addition to
the recommendations of the committee, it is extremely
important to consider inherited predisposition to he-
matopoietic malignancies at the time of selection of any
HLA-matched related donor for allogeneic stem cell
transplantation. An especially notable group of donors
are those found to have mild cytopenias. The recom-
mendation proposed to allow donors with mild anemia
(deﬁned as 2 g/dL below anemia thresholds), mild
neutropenia (deﬁned as <1  109 neutrophils/L), mild
lymphopenia (deﬁned as <.5  109 lymphocytes/L), or
mild thrombocytopenia (deﬁned as between 100 and
130  109/L) absent a contraindication requires further
comment. We and others have found that it is among
this group of donors that workup will have the highest
likelihood of ﬁnding unsuspected inherited hematopoietic
malignancy syndromes [1]. Thus, we propose that
without speciﬁc mention of when and how to evaluate
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recommendation may lead to increased risks for both
donor and recipient and fall short of the outlined prin-
ciples of donor/recipient safety in your consensus
statement.
Allogeneic stem cell transplantation donor evaluation
is a unique opportunity to obtain critical family and
medical history that may uncover a familial pattern of
hematologic disorders that was previously unapparent
from sole evaluation of the recipient. Because most pa-
tients undergoing allogeneic stem cell transplantation do
so for malignant hematopoietic diseases, the family his-
tory of the donor is automatically positive for a he-
matopoietic malignancy in a ﬁrst-degree relative by the
clinical context of the medical encounter. If during the
context of the donor evaluation a clinician newly iden-
tiﬁes that the donor or close relatives are affected by
hematologic disorders, excessive bleeding, mild cytope-
nias, or health conditions known to cluster with heredi-
tary hematologic malignancies, such as primary
lymphedema, this information must be recognized as
important and lead to additional workup. This ﬁrst step
can only be realized if clinicians are knowledgeable about
the signs and symptoms of these disorders.
Familial mutations in several genes are known to confer
increased risk for myeloid malignancies: CEBPA, DDX41,
RUNX1, ANKRD26, ETV6, GATA2, SRP72, TP53, germline
genomic duplications of 14q32.12-q32.2, and the telomere
biology disorders [2-7]; and for lymphoid-based diseases:
ASXL1, ETV6, KMT2A/MLL, KLHDC8B, MKL1, PAX5, and TP53
[4-6,8-12]. The importance of recognition of familial syn-
dromes before allogeneic stem cell transplantation is high-
lighted by numerous examples of poor engraftment, poor
immune reconstitution, and the diagnosis of donor-derived
hematopoietic malignancies in the recipient as well as
hematopoietic malignancies within the donor after stem cell
mobilization when a related donor carrying the familial
mutation has inadvertently been used as the allogeneic stem
cell donor [1,13-15].
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disorders, we have developed an approach at The Uni-
versity of Chicago to aid diverse clinicians in recognizing
donors and families in need of additional evaluation
without adding unnecessary delay or burden to the sys-
tem. To do this, we use a speciﬁc family and medical
history questionnaire at the time of all related donor
evaluations. Key ﬁndings include mild thrombocytopenia
<150  109/L, macrocytosis, or mild anemia of unclear
etiology despite usual workup; unexplained bleeding
diathesis, especially if suggestive of platelet dysfunction;
a family history of hematologic malignancy or aplastic
anemia beyond the patient; or uncommon health condi-
tions such as history of primary lymphedema or pulmo-
nary ﬁbrosis in the donor or family. Because these
disorders are incompletely penetrant and phenotypes
vary in affected individuals even within the same family,
it can be extremely difﬁcult to diagnose these conditions.
Cytopenias and bleeding diatheses may be mild or not
present in individuals carrying a mutation known to
cause these phenotypes in most carriers, such as RUNX1,
for example. Thus, a high index of suspicion and follow-
up of even subtle abnormalities is essential.
If a donor screens positive, we recommend that
either the recipient or donor undergo expedited evalu-
ation by a genetic counselor or hereditary cancer expert
familiar with familial hematopoietic disorders. A clinical
diagnosis of a hereditary hematopoietic disorder can
sometimes be made from this initial evaluation and
expedited genetic testing performed with patient con-
sent to identify the speciﬁc familial mutation and
whether the donor carries that mutation as well. Close
communication with the transplant team is essential
during the process so alternative donor options can be
simultaneously sought. This is critical because a
currently known genetic cause may be identiﬁed in only
a subset of families. Those cases in which the family
history is highly suggestive of a hereditary predisposi-
tion syndrome but the genetic evaluation is negative for
all currently known genes are uniquely challenging. We
use a multidisciplinary conference setting including a
medical ethicist, the transplant donor and recipient
physicians, and geneticist to discuss the speciﬁc case
and outline a consensus recommendation for the family
and unique risks that could be present for this donor
and recipient pair. Special emphasis is placed on the
unique pressures that exist in the donorerecipient
relationship to minimize any coercion to genetic testing
in this scenario, and disclosure of the donor’s genetic
testing results to the recipient are only done with the
donor’s permission, in accordance with the consensus
guidelines for sharing of other medical information. We
realize that access to genetic testing and hereditarycancer expertise may not be available at all centers, but
family historyebased diagnosis in highly penetrant cases
is possible anywhere, especially through teleconsulting
or other means.
With the upcoming World Health Organization 2015
classiﬁcation of leukemias and anticipated inclusion of a
provisional category of germline syndromes predisposing
to myeloid malignancies, we reiterate the importance of
considering familial predisposition syndromes at the time
of evaluation of HLA-matched related donors. We hope
that future consensus recommendation statements will
include a “suitability criteria for family history” section
that details the importance of considering these syn-
dromes and criteria for further evaluation and/or rejec-
tion of donors based on highly suggestive family histories
and/or known germline mutations.
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